Advertisement
Advertisement

HUMA

HUMA logo

Humacyte, Inc. Common Stock

0.99
USD
Sponsored
-0.04
-3.59%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

1.00

+0.01
+0.70%

HUMA Earnings Reports

Positive Surprise Ratio

HUMA beat 12 of 19 last estimates.

63%

Next Report

Date of Next Report
Mar 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.37M
/
-$0.13
Implied change from Q3 25 (Revenue/ EPS)
+81.90%
/
+18.18%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-18.75%

Humacyte, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, HUMA reported earnings of -0.11 USD per share (EPS) for Q3 25, beating the estimate of -0.16 USD, resulting in a 31.89% surprise. Revenue reached 753.00 thousand, compared to an expected 940.78 thousand, with a -19.96% difference. The market reacted with a -2.34% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 1.37 million USD, implying an increase of 18.18% EPS, and increase of 81.90% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Humacyte, Inc. Common Stock reported EPS of -$0.11, beating estimates by 31.89%, and revenue of $753.00K, -19.96% below expectations.
The stock price moved down -2.34%, changed from $1.28 before the earnings release to $1.25 the day after.
The next earning report is scheduled for Mar 26, 2026.
Based on 8 analysts, Humacyte, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of $1.37M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement